News & updates
Facility expansions, platform milestones, regulatory firsts and the partnerships moving living medicines closer to patients.
The new modular suite at our Cambridge, MA headquarters more than doubles allogeneic cell-therapy capacity, adding closed, single-use trains designed for commercial supply. The expansion supports partner programs advancing toward licensure in 2027.
Read moreSolway Bioworks in Galway, Ireland successfully completed a pre-licensing inspection supporting a partner's autologous CAR-T therapy — Solua's 19th regulatory inspection passed across the network and a key milestone on the program's path to commercial approval.
Read moreSolua's proprietary Coherra™ platform now delivers a unified, queryable digital batch record across every GMP site. The rollout shortens batch-review cycles and gives partners a single source of truth from development through commercial supply.
Explore CoherraA multi-year agreement names Solua as the development and clinical-manufacturing partner for an off-the-shelf, iPSC-derived NK-cell therapy. Work spans process development, potency-assay design and GMP supply for first-in-human trials.
Our servicesResponding to growing demand at the cell-free frontier, Solua has formalized an EV development offering — scalable isolation, particle characterization and engineered cargo loading — to help emerging exosome programs build the analytical foundation regulators expect.
EV scienceSince inception, Solua's scientific teams have now completed more than 540 process-development engagements across cell, vector and EV modalities — a body of experience that informs every new partnership we take on.
Meet the teamFor press, speaking requests or partnership conversations, our team is ready to talk.